Drug Details
General Information of the Drug (ID: DR8240) | ||||
---|---|---|---|---|
Name |
Ceftazidime
|
|||
Synonyms |
ceftazidime; Tazidime; 72558-82-8; Fortaz; Pentacef; Tazicef; Ceptaz; ceftazidima; ceftazidimum; Ceftazidime anhydrous; GR 20263; CHEBI:3508; LY 139381; Ceftazidime (INN); Fortaz (TN); GR-20263; LY-139381; CAZ; (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (contains ca. 10% Na2CO3); C22H22N6O7S2; Ceftazidime (TN); Ceptaz (TN); SCHEMBL36849; BIDD:GT0734; CHEMBL44354; DTXSID5022770; J01DD07; HMS2090M13; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; HY-B0593; BDBM50420259; AKOS015951273; CCG-269983; DB00438; NCGC00179584-05; CEFTAZIDIME (ARGININE FORMULATION); AB00513848; C06889; D07654; AB00513848-02; Cefprozil, Antibiotic for Culture Media Use Only; Q-200811; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H22N6O7S2
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
|
|||
InChI |
1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
|
|||
InChIKey |
ORFOPKXBNMVMKC-DWVKKRMSSA-N
|
|||
CAS Number |
CAS 72558-82-8
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Fosfomycin | Streptomyces fradiae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Klebsiella pneumoniae clinical strains | Microorganism model | Klebseilla pneumoniae | |||
Experimental
Result(s) |
The combinations of ceftazidime-avibactam with ertapenem, and ceftazidime-avibactam with tigecycline were able to reduce the MIC to less than the susceptibility breakpoint in all KPC- and OXA-48-producing K. pneumoniae. | |||||
Tea Polyphenols | Theaceae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Klebsiella pneumoniae | Microorganism model | Klebsiella pneumoniae | |||
Experimental
Result(s) |
Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae. | |||||
Zinc oxide | Zincite | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | A. baumannii | Microorganism model | Acinetobacter baumannii | |||
Experimental
Result(s) |
ZnO-NPs potentiate the antimicrobial action of ciprofloxacin and ceftazidime. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Molecule Info | [5] |